Back

Snake venom metalloproteinases are predominantly responsible for the cytotoxic effects of certain African viper venoms

Bartlett, K. E.; Westhorpe, A.; Wilkinson, M. C.; Casewell, N. R.

2024-12-07 pharmacology and toxicology Community evaluation
10.1101/2024.12.04.626778 bioRxiv
Show abstract

AbstractSnakebite envenoming is a neglected tropical disease that causes substantial mortality and morbidity globally. The puff adder (Bitis arietans) and saw-scaled viper (Echis romani) have cytotoxic venoms that cause permanent injury via tissue-destructive dermonecrosis around the bite site. Identification of cytotoxic toxins within these venoms will allow development of targeted treatments, such as small molecule inhibitors or monoclonal antibodies to prevent snakebite morbidity. Venoms from both species were fractionated using gel filtration chromatography, and a combination of cell-based cytotoxicity approaches, SDS-PAGE gel electrophoresis, and enzymatic assays were applied to identify venom cytotoxins in the resulting fractions. Our results indicated that snake venom metalloproteinase (SVMP) toxins are predominately responsible for causing cytotoxic effects across both venoms, but that the PII subclass of SVMPs are likely the main driver of cytotoxicity following envenoming by B. arietans, whilst the structurally distinct PIII subclass of SVMPs are responsible for conveying this effect in E. romani venom. Identification of distinct SVMPs as the primary cytotoxicity-causing toxins in these two African viper venoms will facilitate the future design and development of novel therapeutics targeting these medically important venoms, which in turn could help to mitigate the severe life and limb threatening consequences of tropical snakebite. Key ContributionSVMP toxins were identified as the primary cytotoxicity-causing toxins in the venoms of the puff adder (Bitis arietans) and saw-scaled viper (Echis romani); PII and PIII SVMPs, respectively. This cytotoxicity can be prevented using the metalloproteinase-inhibiting chelator EDTA, suggesting targeted drugs/antibodies may be a viable option for future treatment.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Toxins
14 papers in training set
Top 0.1%
34.6%
2
PLOS Neglected Tropical Diseases
378 papers in training set
Top 0.5%
19.5%
50% of probability mass above
3
PLOS ONE
4510 papers in training set
Top 26%
6.7%
4
Scientific Reports
3102 papers in training set
Top 26%
4.5%
5
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.2%
2.6%
6
International Journal of Biological Macromolecules
65 papers in training set
Top 1.0%
2.5%
7
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.3%
2.2%
8
Nature Communications
4913 papers in training set
Top 53%
1.6%
9
British Journal of Pharmacology
34 papers in training set
Top 0.3%
1.4%
10
Parasites & Vectors
57 papers in training set
Top 1.0%
0.9%
11
Biomedicines
66 papers in training set
Top 2%
0.9%
12
Frontiers in Pharmacology
100 papers in training set
Top 3%
0.9%
13
PLOS Pathogens
721 papers in training set
Top 8%
0.9%
14
eLife
5422 papers in training set
Top 56%
0.8%
15
PeerJ
261 papers in training set
Top 14%
0.8%
16
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
17
Science of The Total Environment
179 papers in training set
Top 5%
0.8%
18
Pathogens
53 papers in training set
Top 2%
0.8%
19
Science Translational Medicine
111 papers in training set
Top 7%
0.7%
20
General and Comparative Endocrinology
18 papers in training set
Top 0.3%
0.7%
21
Biomolecules
95 papers in training set
Top 3%
0.7%
22
Molecular & Cellular Proteomics
158 papers in training set
Top 2%
0.5%
23
BMC Biology
248 papers in training set
Top 6%
0.5%
24
Viruses
318 papers in training set
Top 6%
0.5%
25
Frontiers in Genetics
197 papers in training set
Top 12%
0.5%
26
Communications Biology
886 papers in training set
Top 31%
0.5%
27
Pharmaceuticals
33 papers in training set
Top 2%
0.5%